First-in-human phase I study of JPH203, an L-type amino acid transporter 1 inhibitor, in patients with advanced solid tumors

Abstract

This open-label first-in-human study evaluated JPH203, which is a novel selective L-type amino acid transporter 1 inhibitor. We also evaluated the association between the N-acetyltransferase 2 phenotype and outcomes. Japanese patients with advanced solid tumors received daily intravenous JPH203 treatment for 7days, followed by a 21-day rest period, at escalating doses of 12-85mg/m2. Dose-limiting toxicities were evaluated during the first cycle using a 3 + 3 design. The study enrolled 17 patients, although grade 3 liver dysfunction was detected in one of six patients receiving 60mg/m2 and in the first patient to receive 85mg/m2. Further enrollment was terminated and the maximum tolerated dose was defined as 60mg/m2. The AUC∞ increased between 12mg/m2 and 25mg/m2, although no differences were observed at 25-40mg/m2. Partial response was observed for one patient with biliary tract cancer (BTC) at the 12mg/m2 dose, and disease control was achieved by 3 of 6 patients at the 12mg/m2 and 25mg/m2 dose levels. Based on these results, we recommend a phase II dose of 25mg/m2. The disease control rate for BTC was 60%. Two patients with grade 3 liver dysfunction had the rapid N-acetyltransferase 2 phenotype, and disease control was more common for the non-rapid phenotype (50% vs. 12.5%). It appears that JPH203 was well-tolerated and provided promising activity against BTC. The N-acetyltransferase 2 phenotype might help predict the safety and efficacy of JPH203. Clinical trial registration: UMIN000016546.